Immunology, Neuroscience Step Up as Key Growth Engines for J&J

Key Takeaways J&J's immunology sales fell 12% in 2025 as Stelara dropped 42% after losing exclusivity.J&J saw Tremfya sales jump 41% to over $5B, while Simponi rose 22% to $2.7B.J&J's neuroscience sales climbed 10%, with Spravato up 57% and Caplyta reaching $700M.Johnson & Johnson (JNJ) is one of the key pharmaceutical players in the oncology segment, with its Oncology segment comprising around 27% of total revenues and 42% of its Innovative Medicine segment sales. However, J&J also boasts a strong presence ...